Expanding Access to Generic Oncology Drugs in Emerging Markets
The global generic oncology drugs market is projected to witness a CAGR of 6.6% during the forecast period from 2024 to 2031. It is anticipated to increase from US$ 26.2 Bn recorded in 2024 to a staggering US$ 41.1 Bn by 2031.
Rising cancer rates are driving demand for affordable treatment options, significantly impacting the generic oncology drugs market. The growing acceptance of biosimilars, on the other hand, enhances competition, fostering innovation within the oncology segment.